Lead Product(s) : Rifasutenizol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TenNor Reports Phase III Rifasutenizol Success for H. pylori Infection Treatment
Details : TNP-2198 (rifasutenizol) is a RNAP inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of Helicobacter pylori infection.
Product Name : TNP-2198
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Rifasutenizol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifasutenizol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AMR Action Fund
Deal Size : $42.1 million
Deal Type : Series E Financing
TenNor Raises 300M RMB for Rifasutenizol Development in Heliobacter Pylori
Details : The proceeds will fund the development and to seek regulatory approval in China of TNP-2198 (rifasutenizol), which could become the first drug developed specifically for Helicobacter pylori infection.
Product Name : TNP-2198
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2024
Lead Product(s) : Rifasutenizol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AMR Action Fund
Deal Size : $42.1 million
Deal Type : Series E Financing
Reset All
